drugset
drugset / Trial / NCT06393803

Phase 1 Study of KH607 Tablets

NCT06393803 ↗

Phase 1 Unknown 88 enrolled Chengdu Kanghong Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

This study was a single-center, randomized, double-blind, placebo-controlled study divided into a Single Ascending Dose (SAD) stage and a Multiple Ascending Dose (MAD) stage. The primary objective was to evaluate the safety and tolerability of KH607 tablets in Chinese healthy volunteers.

Timeline

Start
2023-10-21
Primary completion
2024-10-30
Completion
2024-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject KH607 Unknown 2 mg Oral
Subject KH607 Unknown 5 mg Oral
Subject KH607 Unknown 10 mg Oral
Subject KH607 Unknown 20 mg Oral
Subject KH607 Unknown 30 mg Oral
Subject KH607 Unknown 40 mg Oral
Subject KH607 Unknown 50 mg Oral
Subject KH607 Unknown 60 mg Oral

Indications

No indication recorded.